Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria

Frederik Persson, Peter Rossing, Henrik Reinhard, Tina Juhl, Coen D A Stehouwer, Casper Schalkwijk, A H Jan Danser, Frans Boomsma, Erik Frandsen, Hans-Henrik Parving, Frederik Persson, Peter Rossing, Henrik Reinhard, Tina Juhl, Coen D A Stehouwer, Casper Schalkwijk, A H Jan Danser, Frans Boomsma, Erik Frandsen, Hans-Henrik Parving

Abstract

Objective: We investigated whether the antiproteinuric effect of the direct renin inhibitor aliskiren is comparable to that of irbesartan and the effect of the combination.

Research design and methods: This was a double-blind, randomized, crossover trial. After a 1-month washout period, 26 patients with type 2 diabetes, hypertension, and albuminuria (>100 mg/day) were randomly assigned to four 2-month treatment periods in random order with placebo, 300 mg aliskiren once daily, 300 mg irbesartan once daily, or the combination using identical doses. Patients received furosemide in a stable dose throughout the study. The primary end point was a change in albuminuria. Secondary measures included change in 24-h blood pressure and glomerular filtration rate (GFR).

Results: Placebo geometric mean albuminuria was 258 mg/day (range 84-2,361), mean +/- SD 24-h blood pressure was 140/73 +/- 15/8 mmHg, and GFR was 89 +/- 27 ml/min per 1.73 m(2). Aliskiren treatment reduced albuminuria by 48% (95% CI 27-62) compared with placebo (P < 0.001), not significantly different from the 58% (42-79) reduction with irbesartan treatment (P < 0.001 vs. placebo). Combination treatment reduced albuminuria by 71% (59-79), more than either monotherapy (P < 0.001 and P = 0.028). Fractional clearances of albumin were significantly reduced (46, 56, and 67% reduction vs. placebo). Twenty-four-hour blood pressure was reduced 3/4 mmHg by aliskiren (NS/P = 0.009), 12/5 mmHg by irbesartan (P < 0.001/P = 0.002), and 10/6 mmHg by the combination (P = 0.001/P < 0.001). GFR was significantly reduced 4.6 (95% CI 0.3-8.8) ml/min per 1.73 m(2) by aliskiren, 8.0 (3.6-12.3) ml/min per 1.73 m(2) by irbesartan, and 11.7 (7.4-15.9) ml/min per 1.73 m(2) by the combination.

Conclusions: The combination of aliskiren and irbesartan is more antiproteinuric in type 2 diabetic patients with albuminuria than monotherapy.

Trial registration: ClinicalTrials.gov NCT00464880.

Figures

Figure 1
Figure 1
Change in UAER (percentage) versus placebo during treatment with 300 mg aliskiren daily, 300 mg irbesartan daily, or the combination (P

References

    1. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860
    1. Rossing P, Hommel E, Smidt UM, Parving H-H: Reduction in albuminuria predicts a beneficial effect on progression in diabetic nephropathy during antihypertensive treatment. Diabetologia 1994;37:511–516
    1. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870–878
    1. Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CDA, Schalkwijk C, Boomsma F, Frandsen E, Parving H-H: Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008;73:1419–1425
    1. Parving H-H, Persson F, Lewis JB, Lewis EJ, Hollenberg NK: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433–2446
    1. Bröchner-Mortensen J: A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 1972;30:271–274
    1. Hostetter TH, Troy JL, Brenner BM: Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 1981;19:410–415
    1. Trevisan R, Tiengo A: Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens 1995;8:876–883
    1. Imanishi M, Yoshioka K, Konishi Y, Okumura M, Okada N, Sato T, Tanaka S, Fujii S, Kimura G: Glomerular hypertension as one cause of albuminuria in type II diabetic patients. Diabetologia 1999;42:999–1005
    1. Andersen S, Blouch K, Bialek J, Deckert M, Parving H-H, Myers BD: Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int 2000;58:2129–2137
    1. Langham RG, Kelly DJ, Cox AJ, Thomson NM, Holthofer H, Zaoui P, Pinel N, Cordonnier DJ, Gilbert RE: Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002;45:1572–1576
    1. Fisher NDL, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK: Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008;117:3199–3205
    1. Palmer BF: Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002;347:1256–1261
    1. Azizi M, Bissery A, Lamarre-Cliche M, Menard J: Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. Hypertension 2004;43:785-790
    1. Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidyanathan S, Camisasca RP: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004;15:3126–3133
    1. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370:221–229
    1. Rossing K: Progression and remission of nephropathy in type 2 diabetes: new strategies of treatment and monitoring. Dan Med Bull 2007;54:79–98
    1. Sealey JE, Laragh JH: Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007;20:587–597
    1. Danser AHJ, Deinum J: Renin, prorenin and the putative (pro)renin receptor. Hypertension 2005;46:1069–1076
    1. Batenburg WW, de Bruin RJA, van Gool JMG, Muller DN, Bader M, Nguyen G, Danser AHJ: Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008;28:1151–1157
    1. Frandsen E, Boomsma F, Persson F, Dieterich HA, Yeh CM, Dole WP, Lund ED, Prescott M: Renin measurements in the presence of the oral direct renin inhibitor aliskiren: development and validation of a novel high-sensitivity plasma renin activity (hsPRA) assay for measurement of bioactive renin. J Hypertens 2008;26:S383
    1. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324:1098–1104
    1. Parving H-H, Brenner BM, McMurray J, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA: Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24:1663–1671
    1. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547–553
    1. Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, de Champlain J, Weber MA, Raz I: Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial. Kidney Int 2007;72:879–885

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe